Could a diabetes drug and an addiction pill curb alcohol cravings?

NCT ID NCT07249554

Not yet recruiting Disease control Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This Phase 2 trial at Johns Hopkins will test whether combining semaglutide (a GLP-1 drug used for diabetes) with naltrexone (a medication for alcohol dependence) is safe and helps reduce alcohol use. About 45 adults with alcohol use disorder will take the combination or a placebo during a 4-week inpatient program. The study focuses on safety and early signs of effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide and naltrexone combination therapy
What this could lead to: If it works, this could point toward a new treatment option for alcohol use disorder that reduces cravings and drinking.
What could go wrong: This is a small, early Phase 2 trial with only 45 people, so results may not apply broadly. The combination may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Behavior, Addictive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL USE DISORDER

Contacts and locations

Locations

Ashley Addiction Treatment

Havre de Grace, Maryland, 21078, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.